An interesting trend was elucidated by Hay et al. in 2014 16 , where the success rate of drugs entered clinical development in phase I and subsequently approved by the US Food and Drug Administration (FDA) is nearly one-in-six.
← all excerpts
KUALA: a machine learning-driven framework for kinase inhibitors repositioning.
1
—
—